Risk of Mortality Associated With Pimavanserin Use Compared With Other Atypical Antipsychotics in Patients With Parkinson’s Disease–Related Psychosis

21/03/2022
22/09/2025
EU PAS number:
EUPAS46331
Study
Finalised
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

0305976 PDP ACADIA mortality protocol 13AUG2021_signed_redacted

English (1001.36 KB - PDF) View document
Study results
Study report
Other information
Publications
Study publications
Layton JB, Forns J, McQuay LJ, Danysh HE, Dempsey C, Anthony MS, Turner ME. Mor…
Layton JB, McQuay L, Forns J, Danysh H, Dempsey C, Anthony M, Turner ME. Risk o…
Rao S, McQuay LJ, Forns J, MacKay R, Danysh HE, Doshi D, Abler V, Anthony MS, L…
Rao S, McQuay LJ, Forns J, MacKay R, Aquilina TC, Doshi D, Abler V, Anthony MS,…